2016-12-20

Immunovia announces the start of PANFAM-1, the largest ever prospective multi-center clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.

LUND, Sweden, and MADRID, Spain ― Immunovia AB today announced the start of PANFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer (FPC) high risk individuals. The first site now collecting blood samples is the Spanish research center Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe offering FPC screening programs.

Pancreatic cancer continues to have one of the poorest survival rates of any major cancer type. It is widely acknowledged, that the key to improving prognosis and possible successful surgical intervention lies in early detection. Following years of research, Immunovia has developed the first blood based biomarker test to be validated in FPC high risk individuals undergoing annual screening for early pancreatic cancer detection.

“Since 2015, we have been conducting a surveillance program for familiar pancreatic cancer high risk individuals in our center,” says Professor Carrato, Director of the Medical Oncology Department and Scientific Director at IRYCIS. The experience gained has taught us that early detection can lead to successful surgical intervention and to better patient management. For this reason, an accurate reliable blood based test is needed. We are delighted to begin the prospective validation of IMMrayTM PanCan-d as part of our surveillance program of familiar pancreatic cancer high risk individuals and we are looking forward to the results.” 

“For Immunovia, the start of the prospective validation of IMMray TM PanCan-d is a critical milestone which will provide us with the clinical evidence for the test. This longitudinal clinical study, which will analyse one thousand familiar pancreatic cancer high risk individuals over a three year period, will play a major role in the regulatory and reimbursement applications of our test,” commented Mats Grahn, CEO, Immunovia.  

Other confirmed PANFAM-1 partners, also shortly due to commence sample collection, are Mount Sinai in New York and Knight Cancer Institute at Oregon Health and Sciences University, Portland, USA and the University of Liverpool, UK. Immunovia is also in discussions with several other high risk surveillance programs from Europe and USA about their participation.

For more information, please contact:  

Mats Grahn  

Chief Executive Officer, CEO, Immunovia 

Tel.: +46-70-5320230 

Email: mats.grahn@immunovia.com 

Soraya Pérez

Communication, Hospital Ramón y Cajal (HRC)

Tel.: +34 91 336 89 32 / +34 91 336 90 67

Email: soraya.perez@salud.madrid.org / comunicacion.hrc@salud.madrid.org 

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) 

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above. 

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com. 

###